---
authors:
- Castelli, Gregory
- Barlett, Stacy J
category: Case Study
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38574204/
file_path: 2024/03/should-metformin-continue-as-first-line-pharmacotherapy-for.md
issue: '3'
keywords:
- Diabetes Mellitus, Type 2
- Humans
- Sulfonylurea Compounds
- Patients
- Diabetes
- Metformin
- Hypoglycemic Agents
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Metformin
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Sulfonylurea Compounds
- Patients
original_format: PubMed
pages: 200-201
patient_population: Adults
peer_reviewed: true
pmid: '38574204'
processed_date: '2025-07-30'
publication_date: '2024-03-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- editorial
- family-practice
- clinical-medicine
- pubmed-enhanced
title: 'Should Metformin Continue as First-Line Pharmacotherapy for Patients With
  Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.'
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '109'
publication_types: &id001
- Editorial
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '38574204'
  title: 'Should Metformin Continue as First-Line Pharmacotherapy for Patients With
    Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.'
  authors:
  - last_name: Castelli
    fore_name: Gregory
    initials: G
    affiliation: University of Pittsburgh, Pittsburgh, Pennsylvania.
  - last_name: Barlett
    fore_name: Stacy J
    initials: SJ
    affiliation: University of Pittsburgh, Pittsburgh, Pennsylvania.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '109'
    issue: '3'
  publication_info:
    year: '2024'
    month: '03'
    full_date: '2024-03-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Metformin
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Hypoglycemic Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Sulfonylurea Compounds
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Patients
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '38574204'
  title: 'Should Metformin Continue as First-Line Pharmacotherapy for Patients With
    Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.'
  authors:
  - name: Castelli G
    authtype: Author
    clusterid: ''
  - name: Barlett SJ
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Mar
- pmid: '25998308'
  title: Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on
    to metformin therapy in patients with type 2 diabetes? No, it's time to move on!
    Diabetes Care 2015;38:170-175.
  authors:
  - name: Schrijnders D
    authtype: Author
    clusterid: ''
  - name: Houweling ST
    authtype: Author
    clusterid: ''
  - name: Landman GW
    authtype: Author
    clusterid: ''
  source: Diabetes Care
  pubdate: 2015 Jun
- pmid: '25998309'
  title: Response to comment on Genuth. Should sulfonylureas remain an acceptable
    first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's
    time to move on! Diabetes Care 2015;38:170-175.
  authors:
  - name: Genuth S
    authtype: Author
    clusterid: ''
  source: Diabetes Care
  pubdate: 2015 Jun
- pmid: '25139631'
  title: Patterns and determinants of new first-line antihyperglycaemic drug use in
    patients with type 2 diabetes mellitus.
  authors:
  - name: Geier AS
    authtype: Author
    clusterid: ''
  - name: Wellmann I
    authtype: Author
    clusterid: ''
  - name: Wellmann J
    authtype: Author
    clusterid: ''
  - name: Kaj√ºter H
    authtype: Author
    clusterid: ''
  - name: Heidinger O
    authtype: Author
    clusterid: ''
  - name: Hempel G
    authtype: Author
    clusterid: ''
  - name: Hense HW
    authtype: Author
    clusterid: ''
  source: Diabetes Res Clin Pract
  pubdate: 2014 Oct
- pmid: '22926098'
  title: 'Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?'
  authors:
  - name: Christensen M
    authtype: Author
    clusterid: ''
  - name: Knop FK
    authtype: Author
    clusterid: ''
  source: Nat Rev Endocrinol
  pubdate: 2012 Oct
---

# Should Metformin Continue as First-Line Pharmacotherapy for Patients With Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.

**Authors:** Castelli, Gregory, Barlett, Stacy J

**Published in:** American family physician | Vol. 109, No. 3 | 2024-03-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38574204/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sulfonylurea Compounds, Patients

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38574204/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
